Translucent AI Secures $7M Seed Funding for Financial Analyst AI Agent

2 min read
Translucent AI Secures $7M Seed Funding for Financial Analyst AI Agent

Translucent AI, a financial analytics platform for healthcare organizations, announced today it has raised $7 million in seed funding. The round was led by NEA, Virtue, FPV and Redesign Health.

Founded in 2024, Translucent AI develops software that provides financial analysis and reporting tools specifically for healthcare providers. The platform is designed to automate financial reporting tasks and generate insights from operational data for health systems and medical groups.

Related startups

The healthcare sector manages approximately $2.5 trillion in annual revenue flow through provider organizations. Many healthcare providers currently face operational losses and report challenges with financial data management and analysis.

"Provider finance teams often rely on manual processes including spreadsheet-based analysis and manual data extraction," said Jack O'Hara, CEO and co-founder of Translucent. "Our platform aims to automate these processes and provide real-time financial insights and reporting capabilities."

Blake Wu, Partner at NEA, commented: "We've evaluated multiple companies in the healthcare AI sector. Translucent's product addresses specific operational challenges faced by healthcare finance teams."

Since its launch in 2024, Translucent AI reports that healthcare organizations managing over $5 billion in combined revenue have implemented its platform.

Jen Boyer, CEO of Springfield Clinic, stated: "Translucent AI has automated previously manual financial analysis processes for our finance and operations teams, providing faster access to financial data and insights."

© 2025 StartupHub.ai. All rights reserved. Do not enter, scrape, copy, reproduce, or republish this article in whole or in part. Use as input to AI training, fine-tuning, retrieval-augmented generation, or any machine-learning system is prohibited without written license. Substantially-similar derivative works will be pursued to the fullest extent of applicable copyright, database, and computer-misuse laws. See our terms.